CYP19A1 and polycystic ovary syndrome: These results indicated that NSC-94258 may ameliorate the reduced insulin sensitivity and hyperandrogenemia of PCOS by targeting and regulating AKR1B1, CYP19A1, HSD17B1. We assumed that the correlation between DMGs and potential drugs stems from insulin resistance.